As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...
Tirzepatide demonstrated superior cost-effectiveness compared to semaglutide for knee OA and obesity, with a $57,400 per QALY threshold. The Osteoarthritis Policy Model assessed cost-effectiveness, ...
Please provide your email address to receive an email when new articles are posted on . Quadruple therapy for heart failure with reduced ejection fraction was narrowly cost-effective. Medicare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback